Single ChAdOx1 nCoV‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons

Single ChAdOx1 nCoV‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons

Abstract Background Current vaccines against COVID‐19 effectively reduce morbidity and mortality and are vitally important for controlling the pandemic. Between December 2020 and February 2021, adenoviral vector vaccines such as ChAdOx1 (AstraZeneca‐Oxford) were put in use. Recent reports demonstrat...

Full description

Bibliographic Details
Main Authors: Fawzi Ebrahim, Asma Alboueishi, Inas M. Alhudiri, Salah Al Tabal, Yosra Lamami, Samira Al Dwigen, Sondos Ashleb, Noha Ejenfawi, Mohamed B. Milad, Hayat Rhoumah, Salah Edin El Meshri, Adam Elzagheid
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Immunity, Inflammation and Disease
Subjects:
ChAdOx1 (AstraZeneca)
COVID‐19 infection
IgG antibodies
previous infection
SARS‐CoV‐2
Online Access:https://doi.org/10.1002/iid3.1159

Internet

https://doi.org/10.1002/iid3.1159

Similar Items